Search

Your search keyword '"Kurokawa, Ichiro"' showing total 440 results
Start Over Author "Kurokawa, Ichiro"
440 results on '"Kurokawa, Ichiro"'

6. The first nationwide surveillance of antibacterial susceptibility patterns of pathogens isolated from skin and soft-tissue infections in dermatology departments in Japan

Author

Watanabe, Shinichi, Ohnishi, Takamitsu, Yuasa, Akira, Kiyota, Hiroshi, Iwata, Satoshi, Kaku, Mitsuo, Watanabe, Akira, Sato, Junko, Hanaki, Hideaki, Manabe, Motomu, Suzuki, Tamio, Otsuka, Fujio, Aihara, Michiko, Iozumi, Ken, Tamaki, Takeshi, Funada, Yuichi, Shinozaki, Mikio, Kobayashi, Motoko, Okuda, Masaru, Kikyo, Go, Kikuchi, Kumi, Okada, Yoshitane, Takeshima, Masanori, Kaneko, Osamu, Ogawa, Natsuki, Ito, Rie, Okuyama, Ryuhei, Shimada, Shinji, Shimizu, Tadamichi, Hatta, Naohito, Manabu, Maeda, Tsutsui, Kiyohiro, Tanaka, Toshihiro, Miyachi, Yoshiki, Asada, Hideo, Furukawa, Fukumi, Kurokawa, Ichiro, Iwatsuki, Keiji, Hide, Michihiro, Muto, Masahiko, Yamamoto, Osamu, Niihara, Hiroyuki, Takagaki, Kenji, Kubota, Yasuo, Sayama, Koji, Sano, Shigetoshi, Furue, Masutaka, and Kanekura, Takuro

Published
2017
Full Text
View/download PDF

14. Real‐world safety and effectiveness of adalimumab in patients with hidradenitis suppurativa: A 52‐week analysis of a postmarketing surveillance study in Japan.

Author

Hayashi, Nobukazu, Hayama, Koremasa, Takahashi, Kenzo, Kurokawa, Ichiro, Okazaki, Masateru, Kashiwagi, Tomoko, Iwashita, Eri, and Terui, Tadashi

Abstract

Adalimumab is a human monoclonal antibody against tumor necrosis factor‐α that was approved in Japan for the treatment of hidradenitis suppurativa (HS), a chronic recurrent inflammatory skin disease. We report the results of the final analysis of the postmarketing surveillance (PMS) study (ClinicalTrials.gov: NCT03894956), which evaluated the 52‐week safety and efficacy of adalimumab for HS treatment in real‐world clinical practice in Japan. This multicenter, prospective, open‐label, observational study (March 2019 to May 2021) included patients with HS treated with subcutaneous adalimumab at doses following the package insert. The primary endpoint was safety, and the secondary endpoints were effectiveness, including HS clinical response (HiSCR), C‐reactive protein (CRP), skin pain, and Dermatology Life Quality Index (DLQI). Of the 84 patients registered at 65 sites, 83 patients were included in the analyses. Adverse drug reactions (ADRs) were reported by 10 (12.0%) patients; two patients reported a serious ADR, including one patient with serious infection. Other safety events of special interest reported were liver disorder and dermatitis psoriasiform (one patient each). Almost all patients with ADRs were recovering or had recovered, except for one patient who experienced a serious ADR of liver disorder and died. At 12 weeks, 55.4% of patients achieved HiSCR; this increased to 60.5% and 62.8% at 24 and 52 weeks of adalimumab treatment, respectively. Significant reductions from baseline in CRP (P < 0.05), skin pain (P < 0.0001), and DLQI (P < 0.0001) were observed at all time points. The results from this PMS study demonstrated that long‐term adalimumab treatment is well tolerated and effective in patients with HS in real‐world clinical practice in Japan. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

20. Congenital nevi with hypomelanosis and fine scales

Author

Natsuga, Ken, Oiso, Naoki, Kurokawa, Ichiro, Tsubura, Airo, Nakamura, Hideki, Maya, Yuka, Nishie, Wataru, Kawada, Akira, and Shimizu, Hiroshi

Subjects
epidermal nevus, nevus depigmentosus, filaggrin, melanosome, epidermal differentiation, keratin
Abstract

Background: Nevus is a hamartoma or malformation of one or more skin components, resulting in aberrant differentiation of the cell lineage(s) mostly during developmental stages. Although multiple lineages may be involved in a nevus, the combination of melanocyte and keratinocyte abnormalities has been rarely discussed. Objectives. To present two cases of congenital nevi with hypomelanosis and superficial fine scales. Materials & Methods: Skin specimens of the patients were analysed by immunohistochemistry and electron microscopy. Results: Morphological and immunohistochemical studies indicated aberrant epidermal differentiation in the lesional skin specimens. Electron microscopy showed defective melanosome maturation in the melanocytes of the nevi samples. Conclusion: These results demonstrate that both epidermal and melanocytic lineages can concomitantly contribute to the formation of a nevus lesion.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results